PDS Biotech updates corporate presentation deck; no new trial or financial data disclosed

PDS Biotechnology Corp

On September 21, 2026, PDS Biotechnology (NASDAQ: PDSB) posted an updated corporate presentation.
Deck titled 'Overview of PDS Biotech Drug Development Programs (Oncology)' — oncology immunotherapy focus.
Exhibit text provided contains only the cover slide; no dosing, efficacy, or financial figures included.
Filing signed by Frank Bedu-Addo, Ph.D., President and CEO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.